With unique worldwide characteristics, Sinergium Biotech carries out an innovative production model of strategic partnerships with national and international laboratories that allows: the transfer and availability of state-of-the-art technologies, autonomy in the production and supply of strategic products that previously had to be imported, the generation of new sources of employment with highly qualified professionals, the replacement of imports and the generation of an important export potential.
During the influenza A (H1N1) pandemic, the need for a local vaccine production plant in Argentina became evident. In 2010, in partnership with the Swiss company Novartis , the technology transfer process for the local production of influenza vaccines in the country began. In July 2015 bioCSL (a company of the Australian group CSL) and the flu vaccine division of Novartis joined forces to create Seqirus, the second most important company in the world for the production of this vaccine.
This agreement was followed by partnerships with North American companies: Pfizer , for the production of the pneumococcal conjugate vaccine, and MSD (Merck, Sharp &Dohme, an Argentine subsidiary of Merck & Co) for the production of the tetravalent vaccine against HPV. At the same time, for the production of monoclonal antibodies, Sinergium Biotech joins Elea Laboratories, Chemo (with its biotechnology company mAbxience ) and PharmADN who form a public-private consortium together with the Roffo Institute (National University of Buenos Aires), the University of Quilmes , and the Ministry of Science and Technology.
Responsibility and commitment
To take and promote the values, policies and procedures established by the organization and all applicable legal standards. To inspire confidence by developing ourselves with enthusiasm, dedication, initiative, and perseverance
The promotion of good faith interpersonal relationships within and outside the company based on respect and collaboration encourages integration in a good working environment and the achievement of organizational objectives.
Adapting easily and responding effectively to changing contexts is a core competency for our company. To be open to listen, understand and assimilate other points of view, adopting them as our own when circumstances require it.
Orientation towards results
To always seek excellence in the fulfillment of the company, sector and/or position objectives, contemplating the transversal impact of the actions, overcoming difficulties, accepting and/or suggesting opportunities for improvement.
To implement and develop new approaches and techniques to generate value-added solutions. We encourage teams and peers to develop new concepts, methods and approaches for continuous improvement and professional ethics.
Business Development Director
Administration and Finance Director